Urinary Proteomics Combined With Home Blood Pressure Telemonitoring for Health Care Reform

Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age55-75
SponsorKU Leuven

About this trial

UPRIGHT-HTM will compare risk stratification, treatment efficiency and health economic outcomes of a diagnostic approach based on home blood pressure telemonitoring combined with urinary proteomic profiling with home blood pressure telemonitoring alone

Eligibility criteria

Qualifiers

Patients must have at least three additional guideline-defined risk factors, preferably including hypertension, type 2 diabetes mellitus (T2DM), or both;

Patients should be willing patients to engage for the duration of the study in home blood pressure telemonitoring (1 reading per day);

Patients must have an email address and internet access via smartphone, tablet, or laptop or desktop computer;

Patients should comply with the study protocol during the run-in phase.

Disqualifiers

Type 1 diabetes mellitus;

Absence of a practicable echocardiographic window;

Previous or concurrent severe cardiovascular or non-cardiovascular disease;

Cancer within 5 years of enrolment;

Trial design

Treatments tested in this trial

  • In-vitro urinary diagnostic test

Treatment groups

1,000 Participants
are divided into 2 treatment groups

Sponsors and collaborators

KU Leuven

Lead sponsor

Alliance for the Promotion of Preventive Medicine

Collaborator